EGFR-mutation analysis of circulating tumor DNA with high sensitive methods and concordance to effect of EGFR-TKI.

EGFR-mutation analysis of circulating tumor DNA with high sensitive methods and concordance to effect of EGFR-TKI. - Analysis of EGFR mutation from ctDNA

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016348

Enrollment

Registered

2015-01-27

Start date

2012-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

From August 2012 to March 2015

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed non-small cell lung cancer 2. Stage 3B, 4, or recurrent disease 3. EGFR mutation (ex19 deletion, L858R) detected by PNA-LNA PCR clamp method 4. Untreated with EGFR-TKI 5. ECOG performance status (PS) 0 to 2 6. Adequate organ function 7. Aritten informed consent

Exclusion criteria

Exclusion criteria: 1.Received EGFR-TKI before this study 2.Interstitial pmeumonitis or pulmonary fibrosis apparent on chest X-ray 3.Concomitant other malignancies

Design outcomes

Primary

Measure	Time frame
concordance rate of EGFR mutation between tumor and plasma	—

Countries

Japan

Contacts

Public ContactMakoto Maemondo

Miyagi Cancer Center Respiratory Medicine

maemondo-ma693@miyagi-pho.jp022-384-3151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026